Trial Profile
A Phase 2b Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2022
Price :
$35
*
At a glance
- Drugs Tucidinostat (Primary)
- Indications T-cell leukaemia; T-cell lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors HUYA Bioscience International
- 01 Aug 2022 Results published in the Cancer Science
- 23 Jun 2021 According to a HUYA Bioscience International media release, based on data from this trial, Japanese Pharmaceuticals and Medical Devices Agency approved HBI-8000 monotherapy for relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL).
- 06 Oct 2020 According to a HUYA Bioscience International media release, a regulatory application has been submitted to the Japanese Pharmaceuticals and Medical Devices Agency for HBI-8000 monotherapy for relapsed or refractory (R/R) adult T-cell leukemia/lymphoma (ATL).